Results 271 to 280 of about 78,657 (383)

Complexes of Polyethylene Oxide with Guanidine Hydrochloride and with Phenobarbital. Preliminary Structural Studies by Differential Scanning Calorimetry, Polarized Infrared Spectroscopy and X-Ray Fiber Photography

, 1974
Kenji Kono, Y. Takeda, Hisashi Nogami, Tsuneji Nagai   +3 more
openalex   +2 more sources

Alterations in nicotinamide and adenine nucleotide systems during mixed-function oxidation of p-nitroanisole in perfused livers from normal and phenobarbital-treated rats [PDF]

, 1977
Frederick C. Kauffman, Roxanne K. Evans, Ronald G. Thurman   +2 more
openalex   +1 more source

Self‐limited familial focal epilepsy caused by ANK2 variants: A potentially under‐recognized condition

Epilepsia Open, EarlyView.
Abstract The Ankyrin 2 (ANK2) gene encodes the ankyrin‐B protein (ANKB), which is involved in the organization and stability of membrane ion channels, transporters, and receptors in cardiomyocytes and neurons. Variants in ANK2 genes are initially reported in long QT syndrome and autism.
Po‐Hsi Lin, Chen‐Jui Ho, Chih‐Hsiang Lin, Ya‐Yuan Hou, Cheng‐Han Chan, Meng‐Han Tsai   +5 more
wiley   +1 more source

Early Polytherapy for Probably Benzodiazepine Refractory Naïve Status Epilepticus (Stage 1 Plus). [PDF]

Neurol Int
Magro G.
europepmc   +1 more source

Effect of Basic Cupric Acetate on Biochemical Changes in the Liver of the Rat fed Carcinogenic Aminoazo Dye. III. Effect of Copper compared with Some Other Metals, Phenobarbital and 3-Methylcholanthrene on the Metabolism of 4-Dimethylaminoazobenzene

, 1974
Yasuhiro Yamane, Kazuo Sakai
openalex   +2 more sources

Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐TOLE) in adults with focal epilepsy

Epilepsia Open, EarlyView.
Abstract Objective To report interim data from an ongoing, open‐label extension (OLE) of a Phase 2b study (X‐TOLE) of azetukalner in adults with focal onset seizures (FOS) receiving 1–3 antiseizure medications. Methods Eligible participants enrolled in the 7‐year OLE at 20 mg azetukalner once daily with food.
Jacqueline A. French, Roger J. Porter, Emilio Perucca, Martin J. Brodie, Michael A. Rogawski, Cynthia Harden, Jenny Qian, Constanza Luzon Rosenblut, Christopher Kenney, Gregory N. Beatch, X‐TOLE Study Group, Bassel Abou‐Khalil, Sami Aboumatar, Robert Armstrong, Ricardo Ayala, Juan Luis Becerra, Francesca Bisulli, Victor Biton, Christian Brandt, Dulce Campos, Laura Canafoglia, Micaela Chatman, Samuel Destefano, Carlo Di Bonaventura, Toufic Fakhoury, Evan Fertig, Nathan Fountain, Antonio Gambardella, Michael Gelfand, Antonio Gil‐Nagel, Khalid Hamandi, Heidi Henninger, Shahram Izadyar, Sergii Kharchuk, Pavel Klein, Kenneth Laxer, Rebekka Lehmann, Holger Lerche, Andrew Lerman, George Li, Kore Liow, Irene Garcia Morales, Dean Naritoku, Alberto Pinzon‐Ardila, Chiara Pizzanelli, Rodrigo Rocamora, Juan Rodriguez‐Uranga, Joanne Rogin, Felix Rosenow, Ahmed Sadek, Rosa Ana Saiz‐Diaz, Juan Carlos Sanchez, Andreas Schulze‐Bonhage, Pedro Serrano‐Castro, Jose Serratosa, Michael Sperling, Claude Steriade, William Tatum, Christian Tilz, Rafael Toledano, Manuel Toledo, Vicente Villanueva, David Vossler   +62 more
wiley   +1 more source

Lacosamide Boluses Decreased Seizure Burden and Were Well Tolerated in Neonates With Acute Seizures: A Single-Center Retrospective Case Series. [PDF]

J Child Neurol
Jewell TI, Carrasco M, Hsu DA, Knox AT.
europepmc   +1 more source

Excretion of organic acids associated with biotin deficiency in chronic anticonvulsant therapy [PDF]

, 1984
Berlit, Peter, Bonjour, Jean-Pierre, Kochen, W., Krause, Klaus-Henning   +3 more
core  

Efficacy and tolerability of low versus standard daily doses of antiseizure medications in newly diagnosed focal epilepsy. A multicenter, randomized, single‐blind, non‐inferiority trial (STANDLOW)

Epilepsia Open, EarlyView.
Abstract Objective The STANDLOW trial investigated whether first‐line antiseizure monotherapy with low doses has a similar efficacy to standard doses, but with fewer adverse events, improved quality of life, and reduced costs for the National Health System.
Giorgia Giussani, Elisa Bianchi, Edoardo Carlando, Jacopo Cosimo DiFrancesco, Payam Tabaee Damavandi, Francesco Pasini, Giulia Pederzoli, Stefania Filipponi, Alessandra Gaiani, Luca Massacesi, Eleonora Rosati, Ginevra Giovannelli, Teresa Anna Cantisani, Michela Cecconi, Rossella Papetti, Monica Brioschi, Francesco Aruta, Elio Clemente Agostoni, Francesco Paladin, Filippo Dainese, Marco Longoni, Bartolini Yerma, Sara Gasparini, Umberto Aguglia, Edoardo Ferlazzo, Roberto Cantello, Gionata Strigaro, Marta Maschio, Dario Benincasa, Angela La Neve, Giovanni Falcicchio, Alfonso Giordano, Lara Buttarelli, Gabriele Enia, Maurizio Leone, Carlo Ferrarese, Ettore Beghi, Simone Beretta, Andrea Stabile, Susanna Diamanti, Edoardo Pronello, Giulio Pastorelli, Emilio Davide Arippol, Giovanna Straface, Maria Carlini, Maria Grazia Celani, Teresa Francavilla, Angela Alicino, Vittoria Cianci, Maria Sessa, Stefano Martini   +50 more
wiley   +1 more source

Efficacy of phenobarbital is maintained after exposure to mild‐to‐moderate seizures in neonates

Epilepsia Open, EarlyView.
Abstract To study the relationship between the delay in treatment and the efficacy of phenobarbital in neonates, we re‐analyzed data from the NEOLEV2 study. Continuous video EEG (cEEG) from patients treated with phenobarbital was reviewed by neurophysiologists who marked each seizure.
Cynthia Sharpe, Charlotte‐Rose Rennie‐Younger, Dug Yeo Han, Suzanne L. Davis, Mark Nespeca, Francesco Pisani, Jeffrey J. Gold, Gail E. Reiner, Sonya Wang, Richard H. Haas   +9 more
wiley   +1 more source